Skip to main content
Clinical Trials/NCT06342219
NCT06342219
Not yet recruiting
Not Applicable

Study Protocol for a Randomized Controlled Trial of Neurofeedback Mindfulness in Chronic Migraines

University of Saskatchewan1 site in 1 country135 target enrollmentDecember 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Migraine, Headache
Sponsor
University of Saskatchewan
Enrollment
135
Locations
1
Primary Endpoint
Migraine Disability
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

As the second phase of our study on migraine headaches and neurofeedback mindfulness, we will explore how chronic migraineurs will benefit from a long term practice (8 weeks) of neurofeedback mindfulness compared to a similar attention group and a waitlisted group. This randomized controlled trial will also explore if migrianuers could decrease their dependence on medicine intake after completion of the study.

Registry
clinicaltrials.gov
Start Date
December 2024
End Date
June 2026
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Marla Mickleborough

Dr. Marla Mickleborough

University of Saskatchewan

Eligibility Criteria

Inclusion Criteria

  • have a diagnosis of chronic migraine from a clinician or have met the criteria for a chronic migraine diagnosis based on ICHD-3
  • reside in Saskatoon area
  • have a smartphone and internet connection for accessing the MUSE app
  • have no frequent background experience of meditation

Exclusion Criteria

  • Comorbidity of Raynaud's syndrome or diabetes
  • Current use of a preventative migraine treatment over 6 months

Outcomes

Primary Outcomes

Migraine Disability

Time Frame: 8 weeks

measured by Migraine Disability Assessment Scale (MIDAS)

Headache management self-efficacy

Time Frame: 8 weeks

measured by Headache Management Self-Efficacy Scale

Dependence on medicine

Time Frame: 8 weeks

measured by Severity of Dependence Scale (SDS)

Migraine Severity

Time Frame: 8 weeks

measured by Headache Impact Test-short form (HIT-6)

Secondary Outcomes

  • Depression(8 weeks)
  • Anxiety(8 weeks)

Study Sites (1)

Loading locations...

Similar Trials